XTX Ventures has backed Cambridge University spin-out Lucida Medical, which raised seed funding from a group of investors including the Prostate Cancer Research charity.
The capital will aid Lucida Medical in developing its AI technology that more accurately analyses MRI in diagnosing prostate cancer. The investment was in the millions of pounds and is a major advance for the company in its goal of saving time for radiologists and allowing patients to receive the best possible diagnosis and treatment.
The funding from XTX Ventures will be used to extend the team, achieve appropriate . . .
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.